Two Pharmaceutical Companies Update IPO Prospectuses in Race for Billion-Dollar IPOs on HKEX

In the wake of a surge in IPO activities by innovative pharmaceutical companies on the Hong Kong Stock Exchange (HKEX) since 2026, companies like Maywei Biopharma, Engpai Pharmaceuticals, and Danno Pharmaceuticals have successfully listed on the HKEX. Over the past month, the pace of pharmaceutical companies going public in Hong Kong has accelerated once again, with Merit Medical, Borui Pharmaceuticals advancing in the ‘A+H’ listing layout, while companies like Zhixiang Biotech and Shenzhou Cell have also submitted applications for listing on the HKEX. Recently, focusing on the development of new drugs for their own immune and inflammatory diseases, Gaoguang Pharmaceuticals…